1
|
Anwar AZ, Fathelbab TK, Ali AI, Ali MM. A three-step repair of post circumcision coronal fistula: A glans flap, urethral closure, and dartos flap interposition. J Pediatr Surg 2021; 56:1628-1631. [PMID: 33097205 DOI: 10.1016/j.jpedsurg.2020.09.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Revised: 08/31/2020] [Accepted: 09/10/2020] [Indexed: 10/23/2022]
Abstract
PURPOSE To evaluate the outcomes of patients who underwent a post-circumcision coronal fistula repair by means of a three-step repair technique: glans flap, urethral closure, and dartos flap interposition. MATERIALS AND METHODS We retrospectively reviewed the outcomes of 23 patients with postcircumcision urethrocutaneous fistulas who were treated at our institution between January of 2014 and December of 2018. The patients included in this review had exclusively a coronal fistula with an adequate glans bridge between the fistula and the urethral meatus and underwent surgical repair at least 6 months after the initial injury. We excluded from the study patients who had multiple level fistulas, glans dehiscence and patients that were lost to follow-up less than 6 months post fistula repair. RESULTS The median age at the time of the repair was 9.2 (range: 6.3 to 31) months. The fistulas were classified according to their size as small (ranging from pinpoint to ≤4 mm; n = 19) or large (>4 mm; n = 4). The overall success rate was 87% (20 of 23 patients). The success rates for the small and the large fistulas were 94.7% (18 of 19) and 50% (2 of 4), respectively. An indwelling urethral stent was used in all patients, except in those with pinpoint fistulas. The mean follow-up was 19.9 (6-60) months. CONCLUSIONS Post-circumcision coronal urethrocutaneous fistulas less or equal to 4 mm in diameter without glans dehiscence can be successfully repaired using a three-step repair technique, with a recurrence rate of less than 6%. For larger fistulas, a formal urethroplasty is recommended due to high recurrence rate of the three-step repair technique. LEVEL OF EVIDENCE Case Series (Level IV).
Collapse
Affiliation(s)
- Ahmed Zaki Anwar
- Minia University Hospital, Urology Department, Minia, Egypt 61111
| | | | - Ahmed Issam Ali
- Minia University Hospital, Urology Department, Minia, Egypt 61111
| | | |
Collapse
|
2
|
Lucas T, Hines JZ, Samuelson J, Hargreave T, Davis SM, Fellows I, Prainito A, Watts DH, Kiggundu V, Thomas AG, Ntsuape OC, Dare K, Odoyo-June E, Soo L, Toti-Mokoteli L, Manda R, Kapito M, Msungama W, Odek J, Come J, Canda M, Gaspar N, Mekondjo A, Zemburuka B, Bonnecwe C, Vranken P, Mmbando S, Simbeye D, Rwegerera F, Wamai N, Kyobutungi S, Zulu JE, Chituwo O, Xaba S, Mandisarisa J, Toledo C. Urethrocutaneous fistulas after voluntary medical male circumcision for HIV prevention-15 African Countries, 2015-2019. BMC Urol 2021; 21:23. [PMID: 33579261 PMCID: PMC7881669 DOI: 10.1186/s12894-021-00790-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Accepted: 02/01/2021] [Indexed: 02/01/2023] Open
Abstract
Background Voluntary medical male circumcision (VMMC) is an HIV prevention strategy recommended to partially protect men from heterosexually acquired HIV. From 2015 to 2019, the President’s Emergency Plan for AIDS Relief (PEPFAR) has supported approximately 14.9 million VMMCs in 15 African countries. Urethrocutaneous fistulas, abnormal openings between the urethra and penile skin through which urine can escape, are rare, severe adverse events (AEs) that can occur with VMMC. This analysis describes fistula cases, identifies possible risks and mechanisms of injury, and offers mitigation actions. Methods Demographic and clinical program data were reviewed from all reported fistula cases during 2015 to 2019, descriptive analyses were performed, and an odds ratio was calculated by patient age group. Results In total, 41 fistula cases were reported. Median patient age for fistula cases was 11 years and 40/41 (98%) occurred in patients aged < 15 years. Fistulas were more often reported among patients < 15 compared to ≥ 15 years old (0.61 vs. 0.01 fistulas per 100,000 VMMCs, odds ratio 50.9 (95% confidence interval [CI] = 8.6–2060.0)). Median time from VMMC surgery to appearance of fistula was 20 days (interquartile range (IQR) 14–27). Conclusions Urethral fistulas were significantly more common in patients under age 15 years. Thinner tissue overlying the urethra in immature genitalia may predispose boys to injury. The delay between procedure and symptom onset of 2–3 weeks indicates partial thickness injury or suture violation of the urethral wall as more likely mechanisms of injury than intra-operative urethral transection. This analysis helped to inform PEPFAR’s recent decision to change VMMC eligibility policy in 2020, raising the minimum age to 15 years.
Collapse
Affiliation(s)
- Todd Lucas
- Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, GA, USA.
| | - Jonas Z Hines
- Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Julia Samuelson
- Global HIV, Hepatitis, and STIs Programmes, World Health Organization, Geneva, Switzerland
| | | | - Stephanie M Davis
- Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Ian Fellows
- Fellows Statistics, Contractor, Centers for Disease Control and Prevention, San Diego, CA, USA
| | - Amber Prainito
- U.S. Office of the Global HIV/AIDS Coordinator, Washington, DC, USA
| | - D Heather Watts
- U.S. Office of the Global HIV/AIDS Coordinator, Washington, DC, USA
| | - Valerian Kiggundu
- Office of HIV/AIDS, U.S. Agency for International Development, Washington, DC, USA
| | - Anne G Thomas
- Department of Defense, Defense Health Agency, San Diego, CA, USA
| | | | - Kunle Dare
- Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Gaborone, Botswana
| | - Elijah Odoyo-June
- Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Nairobi, Kenya
| | - Leonard Soo
- U.S. Agency for International Development, Nairobi, Kenya
| | | | - Robert Manda
- U.S. Agency for International Development, Maseru, Lesotho
| | | | - Wezi Msungama
- Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Lilongwe, Malawi
| | - James Odek
- U.S. Agency for International Development, Lilongwe, Malawi
| | | | - Marcos Canda
- Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Maputo, Mozambique
| | - Nuno Gaspar
- U.S. Agency for International Development, Maputo, Mozambique
| | | | - Brigitte Zemburuka
- Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Windhoek, Namibia
| | | | - Peter Vranken
- Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Pretoria, South Africa
| | | | - Daimon Simbeye
- Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Dar es Salaam, Tanzania
| | | | - Nafuna Wamai
- Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Kampala, Uganda
| | | | | | - Omega Chituwo
- Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Lusaka, Zambia
| | | | - John Mandisarisa
- Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Harare, Zimbabwe
| | - Carlos Toledo
- Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, GA, USA
| |
Collapse
|